Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,687,000 | 2,368,000 | 477,000 | 1,400,000 | 4,423,000 |
| Depreciation Amortization | 3,014,000 | 3,310,000 | 3,933,000 | 1,518,000 | 1,472,000 |
| Accounts receivable | -275,000 | -190,000 | -207,000 | -177,000 | -171,000 |
| Other Working Capital | -1,331,000 | -148,000 | 1,915,000 | -1,513,000 | -156,000 |
| Other Operating Activity | 1,041,000 | 960,000 | -548,000 | 1,975,000 | -2,602,000 |
| Operating Cash Flow | $6,136,000 | $6,300,000 | $5,570,000 | $3,203,000 | $2,966,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,638,000 | -1,394,000 | -1,135,000 | -1,121,000 | -1,110,000 |
| Net Acquisitions | -122,000 | -6,000 | -11,141,000 | -55,000 | 2,285,000 |
| Purchase Of Investment | -103,000 | -131,000 | -210,000 | -2,823,000 | -4,933,000 |
| Sale Of Investment | 21,000 | 73,000 | 129,000 | 3,709,000 | 4,112,000 |
| Other Investing Activity | 27,000 | 102,000 | 2,739,000 | 42,000 | 52,000 |
| Investing Cash Flow | $-1,815,000 | $-1,356,000 | $-9,618,000 | $-248,000 | $406,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -26,000 | -1,034,000 | -1,767,000 | -1,281,000 |
| Debt Issued | 1,842,000 | 4,009,000 | 6,742,000 | 14,934,000 | 2,485,000 |
| Debt Repayment | -3,441,000 | -12,433,000 | -8,650,000 | -12,000 | -57,000 |
| Common Stock Issued | 298,000 | 271,000 | 350,000 | 248,000 | 314,000 |
| Common Stock Repurchased | -718,000 | -238,000 | -117,000 | -522,000 | -2,237,000 |
| Dividend Paid | -2,270,000 | -1,974,000 | -1,849,000 | -1,539,000 | -1,443,000 |
| Other Financing Activity | 0 | 0 | -723,000 | -195,000 | -17,000 |
| Financing Cash Flow | $-4,289,000 | $-10,391,000 | $-5,281,000 | $11,147,000 | $-2,236,000 |
| Exchange Rate Effect | -16,000 | -116,000 | 116,000 | -483,000 | -198,000 |
| Beginning Cash Position | 3,844,000 | 9,407,000 | 18,620,000 | 5,001,000 | 4,063,000 |
| End Cash Position | 3,860,000 | 3,844,000 | 9,407,000 | 18,620,000 | 5,001,000 |
| Net Cash Flow | $16,000 | $-5,563,000 | $-9,213,000 | $13,619,000 | $938,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,136,000 | 6,300,000 | 5,570,000 | 3,203,000 | 2,966,000 |
| Capital Expenditure | -1,638,000 | -1,394,000 | -1,135,000 | -1,121,000 | -1,110,000 |
| Free Cash Flow | 4,498,000 | 4,906,000 | 4,435,000 | 2,082,000 | 1,856,000 |